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Abstract. The preclinical stage of frontotemporal lobar degeneration (FTLD) is not well characterized. We conducted a brain
metabolism (FDG-PET) and structural (cortical thickness) study to detect early changes in asymptomatic GRN mutation carriers
(aGRN+) that were evaluated longitudinally over a 20-month period. At baseline, a left lateral temporal lobe hypometabolism
was present in aGRN+ without any structural changes. Importantly, this is the first longitudinal study and, across time, the
metabolism more rapidly decreased in aGRN+ in lateral temporal and frontal regions. The main structural change observed in
the longitudinal study was a reduction of cortical thickness in the left lateral temporal lobe in carriers. A limit of this study is
the relatively small sample (n = 16); nevertheless, it provides important results. First, it evidences that the pathological processes
develop a long time before clinical onset, and that early neuroimaging changes might be detected approximately 20 years
before the clinical onset of disease. Second, it suggests that metabolic changes are detectable before structural modifications
and cognitive deficits. Third, both the baseline and longitudinal studies provide converging results implicating lateral temporal
lobe as early involved in GRN disease. Finally, our study demonstrates that structural and metabolic changes could represent
possible biomarkers to monitor the progression of disease in the presymptomatic stage toward clinical onset.
Keywords: Cortical thickness, dementia, frontotemporal dementia, frontotemporal lobar degeneration, GRN, longitudinal, pre-
clinical study, presymptomatic, progranulin, PET
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) are rare
neurodegenerative disorders characterized by behav-
ioral changes and language deficits. Mutations of
the GRN (progranulin) gene, all leading to progran-
ulin haploinsufficiency, are responsible for 25% of
familial cases. The prevalent clinical phenotype of
GRN patients is behavioral variant of frontotempo-
ral dementia (bvFTD). Primary progressive non-fluent
aphasia and corticobasal syndrome are less common
presenting phenotypes [1, 2]. Neuroimaging pattern of
GRN carriers is characterized by asymmetrical fronto-
temporal-parietal atrophy [3, 4].
So far, it is not known how long structural and
functional changes occur before the clinical onset of
FTLD disease. It is expected that biological alterations
and morphological changes leading to dementia could
occur decades before the first symptoms of FTLD,
as demonstrated in other genetic forms of dementias
such as Alzheimer’s disease [5]. Establishing how long
these brain changes precede the clinical onset and their
chronology during the presymptomatic stage is cru-
cial because therapeutics such as HDAC inhibitors
or amiodarone [6–8] are currently being developed
to compensate progranulin haploinsufficiency. In this
study, we performed a multimodal approach to inves-
tigate the chronology of brain structural and metabolic
changes in a cohort of asymptomatic GRN carriers.
MATERIALS AND METHODS
Subjects
Forty-three neurologically healthy individuals with
50% risk to carry a GRN mutation (first degree rela-
tives of GRN carriers from 15 unrelated families) were
recruited in four French centers over a 3-years period
(2011 to 2013). All participants have signed informed
consent for the study that was approved by the Ethics
Committee of ‘Assistance Publique-Hopitaux de Paris,
Paris’.
At inclusion, asymptomatic status was ascertained
based on relative’s interview, neurological examination
and the normality of scores of behavioral scales and
neuropsychological tests (Supplementary Methods 2,
Supplementary Table 1). Three participants presented
cognitive impairment at neuropsychological evalua-
tion and were considered as ‘cognitively symptomatic
non dementia’ (CSND); therefore, they were excluded
from the analyses. Additionally, 7 were also excluded
from analyses because they did not undergo the full
protocol, or because of the discovery of coincidental
lesions on brain MRI a posteriori.
Finally, 33 healthy individuals were included in
the analyses. GRN sequencing revealed that six-
teen asymptomatic participants carried GRN mutation
(aGRN+, see Supplementary Table 2 for the list of
mutations); the 17 participants who did not carry
mutation (GRN−) were used as control group. The
characteristics of aGRN+ and GRN− groups are sum-
marized in the Table 1 and Supplementary Table 1.
There were no statistical differences in age at exam-
ination, gender composition, and educational level
between the two groups (Table 1, Supplementary
Methods 1). The 33 subjects underwent standard MRI
and FDG-PET study at baseline (T0); all except 5
underwent a second evaluation 20 months later (T20)
with the same cognitive and neuroimaging protocol
(14 GRN carriers, 14 non-carriers, n = 28) (Table 1).
Five participants (2 carriers, 3 non-carriers) refused
to be reevaluated and dropped out the study. Baseline
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Table 1
Demographic characteristics of GRN carriers (aGRN+) and controls (GRN−)
Baseline visit (T0) Follow-up visit (T20)
Genetic status aGRN+ GRN− p-value aGRN+ GRN− p-value
Number of cases 16 17 – 14 14 –
Gender Male/Female 4/12 6/11 – 4/10 5/9 –
Education level (mean score) 2.7 ± 0.5 2.8 ± 0.5 0.8 – – –
Age at examination, 41.9 ± 8.2 40 ± 8.3 0.8 43 ± 7.9 42.1 ± 9.0 0.9
years (range) (27–58) (27–60) (28–59) (29–51)
Duration T0–T20, months – – – 19.5 ± 2 20.0 ± 6.2 0.9
Distance to estimated age at 20 ± 10 – – – – –
onset, years (range) (7–34)
Means ± SD are reported. Significant p-value <0.05. Educational level has been scored as follow: score 1 (5–8 years of study); score 2 (9–12
years); score 3 (>12 years).
and longitudinal statistical analyses were performed
for brain structural MRI and metabolism, as described
below. The participants were age- and gender-matched
for the analyses at each time points (Table 1). We esti-
mated the distance from the age of clinical onset in
aGRN+ by subtracting the age at examination to the
mean age at onset in the family.
MRI protocols
MRI acquisition
MRIs were acquired with 3 Tesla and 1.5 Tesla scan-
ners according to the scanner available in each center.
All centers used the same MRI sequences protocol
that was designed and optimized to minimize centers
bias. Prior to the study, phantom acquisitions were per-
formed in order to ensure the comparability of the
results across centers. The same proportion of carri-
ers and of non-carriers was investigated in each center,
and baseline and follow-up MRIs were performed on
the same scanners for each participant. High-resolution
three-dimensional T1-weighted images were acquired
with full brain coverage and isotropic voxels (TR:
2300 ms; TE: 4,18 ms; matrix = 256 mm; slice thick-
ness = 1 mm).
Cortical thickness analysis
Cortical thickness analyses were performed on T1-
weighted 3D images using Freesurfer software (http://
surfer.nmr.mgh.harvard.edu). Briefly, T1-weighted 3D
images were preprocessed with intensity variations
correction, normalization, affine registration to the
Talairach atlas, skull stripping, and segmentation of
grey and white matter. The pipeline for longitudinal
processing has been used that includes the creation
of an unbiased within-subject template using robust,
inverse consistent registration [9]. For cortical thick-
ness, we used surface-based analysis of thickness
values at each vertex. Surface-based analyses of corti-
cal thickness were performed using Surfstat software
(http://www.math.mcgill.ca/keith/surfstat/) following
the methodology previously used [10]. Cortical thick-
ness maps were smoothed using a 20 mm surface-based
kernel. The comparison of baseline cortical thickness
between groups was carried out using a two-sample t-
test at each vertex. For longitudinal analyses, a paired
t-test was used. Statistics were corrected for multi-
ple comparisons using the random field theory for
non-isotropic images [11]. A statistical threshold of
p < 0.005 was first applied (height threshold). An extent
threshold of p < 0.05 corrected for multiple compar-
isons was then applied at the cluster level.
Positon emission tomography protocols
18Fluorodeoxyglucose positon emission tomog-
raphy (18FDG-PET) scans were acquired in four
departments of nuclear medicine with a standardized
protocol. Phantom acquisitions were performed prior
to the study in order to measure the spatial resolution
(FWHM) of each scanner. A dose of 2 MBq/Kg of flu-
orodeoxyglucose (18FDG) was injected 30 to 45 min
prior to an acquisition of 15 min. Patients rested in quiet
surroundings with the eyes closed at least 20 min post-
injection. Follow-up scans were performed on the same
tomograph as the baseline, with the same protocol.
PET volumes were co-registered to their corre-
sponding MRI volumes. MRI volumes were segmented
into grey matter and white matter probability maps
and spatially normalized to MNI space using SPM8.
PET co-registered images were spatially normal-
ized applying the transformation parameters of MRI
normalization. Individual variability was taken into
account by dividing for each subject voxel uptake by
the mean pons uptake, yielding parametric images.
Pons uptake was obtained from a Pickatlas (http://fmri.
wfubmc.edu/software/pickatlas) region of interest.
Parametric images were smoothed using an isotropic
Gaussian kernel of 12 mm. Voxel-by-voxel comparison
between carriers and non-carriers was then performed
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with a two-sample T-test on smoothed parametric
images using an explicit mask. This mask was obtained
from the mean of grey matter probability maps of each
subject included in this analysis, with a threshold of
0.4. Age, gender, and tomograph spatial resolution
were used as covariates. MarsBaR toolbox in SPM8
was used to extract [18F]FDG-uptake adjusted values
from significant clusters.
The method used to analyze the longitudinal data
has been adapted from the one previously described
by Fouquet et al. [12]. The follow-up MRI was co-
registered to the baseline MRI, and a mean image
was calculated. This mean image was used to calcu-
late optimal transformation parameters to MNI space.
Next, baseline and follow-up PET images were co-
registered to the baseline MRI, spatially normalized
to MNI using optimal transformation previously cal-
culated, scaled with mean pons uptake, and smoothed
with an isotropic Gaussian kernel of 4 mm. Individ-
ual percent annual changes maps or “PET-PAC” were
then calculated. These maps represent the voxel-wise
calculation of percent metabolic change over the 20-
month follow-up period (i.e., the difference between
follow-up and baseline scaled PET value divided by
baseline PET value x 100) expressed in annual percent
change. A voxel-by-voxel comparison of PET-PAC
between carriers and non-carriers was then performed
after a second smoothing of the individual PET-PAC
maps with an isotropic Gaussian kernel of 10 mm, and
using a mask obtained with the same method as for the
cross-sectional analysis.
All results are reported with p-value <0.001 uncor-
rected for multiple comparisons with an extent
threshold k corresponding to the expected number of
voxels per cluster. Differences in spatially normalized
FDG-PET scans obtained with scanners of different
resolutions were minimized by the following mea-
sures: i) restricting the analysis to voxels with intensity
80% greater than the whole-brain mean, and ii) exclud-
ing voxels from the uppermost 10 slices (i.e., from the
top 22.5 mm of the brain) and from the lowermost 5
slices, where significant inter-scanner effects due to
different fields of view have been reported [13].
RESULTS
Groups did not differ for gender, age at examination
(p = 0.8), age at follow-up (p = 0.9). The mean esti-
mated distance to the age at clinical onset was 20 ± 10
years in aGRN+ (Table 1).
Cortical thickness
At baseline, no significant difference was found for
cortical thickness between aGRN+ and GRN−. At
follow-up a reduction of cortical thickness was found
in one cluster in the left middle (1607 voxels) and infe-
rior (554 voxels) temporal gyri (Fig. 1) in aGRN+,
L 0.05 0.025 0.005 0.025
P cluster P vertex
0 R
Fig. 1. Cluster with significant cortical thickness changes in aGRN+ between the two time-points (p < 0.05 corrected). L, left; R, right.
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Fig. 2. a) At baseline PET-FDG hypometabolism in aGRN+ compared to GRN- (p < 0.001 uncorrected). L, left; R, right. b) The plot of the
adjusted values of [18F]FDG uptake in the cluster is reported. Horizontal line corresponds to the median. GRN−: non carriers, aGRN+:
asymptomatic GRN mutation carriers.
with peak in the left middle temporal gyrus (p < 0.05,
cluster-corrected).
18Fluorodeoxyglucose-PET
At baseline a left middle temporal gyrus
hypometabolism (183 voxels; MNI coordinates
x = −50; y = −40; z = −2) was present in aGRN+
compared to GRN- (p < 0.001 uncorrected) (Fig. 2).
The longitudinal analysis revealed areas of greater
metabolism decrease (p < 0.001, uncorrected) in
aGRN+ compared to GRN− in the left inferior
temporal, left middle frontal, left inferior orbital
frontal, right superior orbital frontal gyri as well as
in the left thalamus (Fig. 3; Supplementary Table 4).
Mean and maximal percent annualized change values
in the regions represented in Fig. 3 are given in
Supplementary Table 4.
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Fig. 3. Regions of greater percentage of annualized changes of metabolism in aGRN+ compared to GRN− (p < 0.001 uncorrected). L, left; R,
right (see Supplementary Table 4 for MNI coordinates and for values).
DISCUSSION
The major neuroanatomical signature of GRN dis-
ease in symptomatic patients carrying mutations is an
asymmetric involvement of the inferior frontal, tem-
poral, and parietal brain regions [1, 3, 4]. A recent
study also demonstrated that the most important annual
percentage change of atrophy occurs in temporal lobe
(lateral, polar), parietal (lateral, posterior) lobes, and
insula in GRN symptomatic patients, compared to all
other genotypes [14].
In this study, we have evaluated the presymp-
tomatic phase of GRN disease. We have conducted
a multimodal analysis combining two neuroimaging
approaches to evaluate the chronology of structural
and metabolic brain changes occurring during the
presymptomatic phase in GRN carriers. The mean dis-
tance from estimated age at onset in our series (20 ± 10
years) is longer than in most other studies (7 to 12
years, Supplementary Table 5) and allows detecting
very early changes. We also evaluated the progression
of brain changes across time in a longitudinal study.
Importantly, this is the first longitudinal study con-
ducted inGRN disease. In most studies, the progression
in presymptomatic stage of dementia is evaluated by
correlating changes to the mean distance to clinical
onset, estimated as the difference between age at exam-
ination and mean age at onset in a family [15–18].
This estimation can be easily applied in genetic dis-
eases where age at onset is relatively stable within
families, as in genetic forms of Alzheimer’s disease
[5], but this approximation is less confident in GRN
disease, where age at onset is highly variable within
families. For this reason, we evaluated the progres-
sion of changes across time by longitudinal evaluation
of presymptomatic GRN carriers, during a 20-month
follow-up period.
At baseline, the absence of structural changes mea-
sured by cortical thickness in this study is consistent
with one other study [18]. These negative results might
be explained by the long distance to clinical onset. Oth-
erwise, this method might be not sensitive enough to
detect small effects in small groups of asymptomatic
individuals. Only one cross-sectional study performed
by Pievani et al. demonstrated reduced cortical thick-
ness in five GRN carriers in the orbitofrontal cortex,
middle frontal and precentral gyri that are not com-
pletely consistent with our results at baseline [19].
These inconsistencies might be due the age at exami-
nation that is higher than in our study, the population
is thus closer to clinical onset, and to the sample size
of carriers which is smaller than our cohort, possibly
explaining different results at baseline. Furthermore,
statistical methodology in our study is less liberal than
that used by Pievani et al. and shall minimize the report
of false positive findings. This may also explain why
Pievani et al reported differences in a smaller group of
carriers while we did not find significant differences at
baseline. Importantly, even if no changes were present
at baseline in our study, the cortical thickness reduced
across time at follow-up in our aGRN+ individuals in
lateral temporal lobe, in particular in the left middle and
inferior temporal gyri. Notably, accordingly with our
results, cortical thickness decreased faster with aging
in the same regions in GRN carriers in another study
[18]. Our results indicate that a comparison across time
might be an appropriate method to detect affected brain
regions during the presymptomatic stage.
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Hypometabolism was present at baseline in GRN
carriers and was initially limited to the left mid-
dle temporal region. Unexpectedly, frontal lobes
were not involved at baseline, although another
metabolism study in aGRN+ carriers [17] found dif-
fuse hypometabolism in frontal lobes. In the latter
study, however, half of 9 carriers were cognitively
symptomatic, which might explain less selective
impairment at a later stage of disease progression.
These inconsistencies can also be partially related to
different methodologies used in the two studies. Con-
versely, our follow-up evaluation evidenced a rapid
metabolism decrease in aGRN+ involving the frontal
lobe (left middle, orbital) in addition to the inferior
temporal gyrus and thalamus. Our results suggest that
metabolic abnormalities, detectable at baseline, could
predate the structural changes, and be one of the earliest
predictor of the pathological process. It also suggests
that temporal lobe might be initially more susceptible
to the pathological process which secondarily progress
to the frontal cortex.
Finally, both our baseline and longitudinal studies
provide converging results implicating the lateral tem-
poral lobe as one of the earliest regions involved in
GRN disease. Other studies [15, 20] also indicate that
temporal areas could be noticeably impaired, before
the frontal regions. A recent European study in a large
cohort of aGRN+ carriers demonstrates that tempo-
ral atrophy is detectable 15 years before estimated
clinical onset, before frontal involvement [21]. Con-
sequently, one might hypothesize a dynamic model
of the presymptomatic stage of GRN disease where
temporal areas, involved many years before the clini-
cal onset, could be the ‘epicenter’ of the pathological
seeds, that might progress later toward frontal and/or
parietal regions.
The left middle temporal gyrus, which is early and
consistently involved in this study, is implicated in
language and semantic processing as well as in the
recognition and retrieval of semantic information [22].
The involvement of this region fits well with clinical
presentation of language disorders, especially agram-
matic/nonfluent variant of FTD, characterizing a subset
of GRN patients [1, 3]. The lateral temporal lobe also
plays a role in theory of mind [23] that is one of the
first detectable cognitive deficits in the early stage of
FTD, and that significantly decreases in GRN carriers
approaching the age of onset of the disease [16].
A more rapid metabolic decrease was also detected
in the thalamus, a key node in the prefrontal-basal
ganglia circuits, as well as in the prefrontal cor-
tex. Interestingly, thalamic atrophy is more frequently
detected in symptomatic GRN carriers than in other
FTD subtypes [24], and already detected in the
presymptomatic stage of FTD [21]. Both thalamus and
the prefrontal cortex generate and control goal-directed
behaviors [25, 26] and are implicated in apathy, one of
the predominant clinical symptom of FTD.
Studies in GRN presymptomatic carriers have some
limitations. First, clinical heterogeneity of GRN dis-
ease, reflecting variable topography of lesions at
onset, can diminish robustness of changes detection
in presymptomatic carriers. Moreover, subtle changes
detected during the presymptomatic stage, could also
vary according to methodological approaches. Finally,
disease-specific markers are not available in FTLD,
thus possibly delaying the detection of presymptomatic
changes in this pathology.
However, our study provides important results. First,
it evidences that the pathological process develop
a long time before clinical onset in GRN carriers,
and that early metabolic changes might be detected
approximately 20 years before estimated disease onset.
Second, it shows that metabolic changes are detectable
before structural modifications and cognitive deficits
that possibly appear in a shorter delay from the clini-
cal onset. Finally, our study contributes to demonstrate
that structural and metabolic changes could represent
possible biomarkers to monitor the progression of dis-
ease in the presymptomatic stage toward the clinical
onset.
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